Compass Pathways Shares Climb 7.5% on Strong Phase 2 Data and H1 2027 Approval Outlook
COMP•Compass Pathways shares rose 7.51% after-hours after the company reported strong Phase 2 efficacy and safety results for its COMP360 psilocybin therapy in treatment-resistant depression. An analyst forecasts FDA approval by H1 2027 or sooner based on the trial’s robust remission rates and tolerability.
1. Phase 2 Trial Results
Compass Pathways reported strong efficacy and safety outcomes from its COMP360 Phase 2 trial in treatment-resistant depression, highlighting high remission rates sustained over several weeks and a favorable tolerability profile with minimal severe adverse events.
2. Analyst Approval Timeline
An industry analyst projects FDA approval by H1 2027 or sooner, citing the trial’s statistically significant endpoints and the potential for an accelerated regulatory review given the unmet need in refractory depression treatment.
3. Market Reaction
Following the positive trial data and optimistic approval timeline, Compass Pathways shares jumped 7.51% in after-hours trading, reflecting heightened investor confidence in the company’s lead psychedelic therapy candidate.
